Form 4: Myriad Genetics Chief Scientific Officer Reports Stock Transactions
SEC Form 4 Filing
Dale Muzzey, Chief Scientific Officer of Myriad Genetics, reports acquisition of restricted stock units and subsequent disposal of shares to cover tax obligations.
Summary
- On March 14, 2024, Dale Muzzey, the Chief Scientific Officer of Myriad Genetics, acquired 49,250 shares of common stock through time-based restricted stock units.
- These restricted stock units vest in three equal annual installments starting one year from the grant date.
- On March 15, 2024, Muzzey disposed of 3,322 shares at a price of $21.16 to cover tax withholding obligations related to the vesting of the restricted stock units.
- Following these transactions, Muzzey directly owns 113,401 shares of Myriad Genetics.
- The transactions were reported on Form 4, filed with the SEC on March 18, 2024.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the transactions are routine and related to executive compensation.
Industry Context
Executive stock transactions are a common occurrence in publicly traded companies and are often related to compensation packages. These transactions are closely monitored by investors for insights into management's confidence in the company's future prospects.
Key Dates
| Date | Description |
|---|---|
| 03/14/2024 | Acquisition of 49,250 shares of common stock through restricted stock units. |
| 03/15/2024 | Disposal of 3,322 shares at $21.16 to cover tax obligations. |
| 03/18/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.